Marc O’Connor writes in MedCity News:
“The pharmaceutical industry is about to wade into a new battlefield with payers and prescribers. A new class of drugs known as PCSK9 inhibitors restricts a protein that impedes the liver’s ability to get rid of bad cholesterol. FDA approval of the first in this new class of drugs is expected within months if not sooner. The implications for improving the lives of the millions of Americans affected by heart disease is significant. And the prospective cost to payers and plan sponsors could be astronomical.”
$1,00o a month per patient?! This could blow up the Medicare budget.
Just consider that there are tens of millions of Americans with high cholesterol.
